Recludix Pharma, a leader in platform approaches to discover
inhibitors of challenging cancer and inflammatory disease targets,
today announced the establishment of its scientific advisory board.
“We are thrilled to have established a group of distinguished
scientific thought leaders as advisors to the company,” said Nancy
Whiting, Pharm.D., chief executive officer of Recludix. “Our
scientific advisory board consists of pioneers in precision
medicine for both oncology and inflammatory diseases. Their deep
and diverse expertise will prove invaluable as we advance our
pipeline of potent and selective oral inhibitors of important
targets that have historically been challenging to drug.”
Brian Druker, M.D., director of the Knight Cancer Institute,
associate dean for oncology, and JELD-WEN chair of leukemia
research at the Oregon Health & Science University, added, “The
differentiated development candidates being generated by Recludix’s
platform to selectively inhibit the once-elusive, but critical,
targets of STAT3 and STAT6 could yield transformational new
therapies. I am looking forward to working with the Recludix team
to advise on current and future research activities as Recludix
continues to advance these and the other promising candidates in
their pipeline to bring new medicines to patients in need.”
Scientific Advisory Board Members
Brian Druker, M.D.Dr. Druker is the director of
the Knight Cancer Institute, associate dean for oncology, and
JELD-WEN chair of Leukemia Research at the Oregon Health &
Science University in Portland, OR. A pioneer in the field of
precision medicine, his research focuses on translating knowledge
of the molecular pathogenesis of cancer into specific therapies and
investigating the optimal use of these molecularly targeted agents.
Dr. Druker’s research led to the first drug to target the molecular
defect of a cancer while leaving healthy cells unharmed—imatinib
(Gleevec) for chronic myeloid leukemia. He performed the
preclinical studies that led to its development and then
spearheaded the clinical trials that led to Food and Drug
Administration approval of imatinib in record time. The drug
changed the life expectancy of patients with chronic myeloid
leukemia from an average of three to five years to a 95% survival
rate at five years. The approach has led to a paradigm shift in
cancer treatment from nonspecific chemotherapy to targeted
therapeutic agents, spurring the development of numerous precision
therapies for other cancers. Dr. Druker has served as a member of
the Board of Scientific Advisors to the National Cancer Institute
and on the board of directors of the American Association for
Cancer Research. He is a member of the National Academy of Medicine
and the National Academy of Sciences. Among his many awards, he
received the Lasker-DeBakey Clinical Medical Research Award.
Carlos Garcia-Echeverria, Ph.D.Dr.
Garcia-Echeverria has provided scientific leadership to drug
discovery and early clinical development teams across different
modalities and diseases. He currently serves as the chief of Rx
creation at EQRx, leading the research and early-stage development
functions. Previously, he was the chief operating officer of
research at Sanofi where he oversaw the establishment and execution
of the mid- and long-term vision and strategy of global research
for effective portfolio management. Prior to Sanofi, Dr.
Garcia-Echeverria was a member of the leadership team and global
oncology decision board at the Novartis Institute for Biomedical
Research. He has also broad experience in managing research
partnerships. His research accomplishments are documented by 190
peer-reviewed articles, book chapters and review papers, as well as
45 granted patents.
Dr. Garcia-Echeverria holds a Ph.D. in organic chemistry from
the University of Barcelona and received the Leonidas Zerwas Award
from the European Peptide Society in recognition of his outstanding
contributions to peptide science.
Stefan Knapp, Ph.D.Dr. Knapp is the chief
scientific officer of the Structural Genomics Consortium (SGC) and
professor of pharmaceutical chemistry at the Goethe-University
Frankfurt. His research interests are the rational design of
selective inhibitors that target protein kinases as well as protein
interactions modules that function as reader domains of the
epigenetic code. He joined Frankfurt University (Germany) in 2015
as a professor of pharmaceutical chemistry in the Institute of
Pharmaceutical Chemistry and the Buchmann Institute of Molecular
Life Sciences.
From 2012 and 2015 he was the director for Chemical Biology at
the Target Discovery Institute (TDI), and between 2008 to 2015 he
was a professor of structural biology at the Nuffield Department of
Clinical Medicine (NDM) at Oxford University (UK). Previously, he
was a principal research scientist in structural biology and
biophysics at Pharmacia Corporation.
Dr. Knapp studied chemistry at the University of Marburg
(Germany) and at the University of Illinois (USA). He did his Ph.D.
in protein crystallography at the Karolinska Institute in Stockholm
(Sweden) and continued his career at the Karolinska Institute as a
postdoctoral scientist.
Marco Londei, M.D.Dr. Londei most recently was
the chief executive officer of Gadeta. Previously, he was the chief
development officer and chief medical officer of AnaptysBio
(NASDAQ: ANAB), where he played a crucial role in the company’s
transition from a preclinical phase to its successful IPO, and
several rounds of financing as a clinical stage biopharmaceutical
company. Prior to AnaptysBio, Dr. Londei held leadership roles at
Novartis and Bristol-Myers Squibb, in charge of global teams for
clinical development in transplantation, autoimmune and
inflammatory disease areas. Over the 15 years in the pharma
industry, Dr. Londei and his team brought more than a dozen of new
molecular entities into clinical development, six of which have
since entered the market. Before his move to the pharmaceutical
industry, Dr. Londei was professor of medicine at Imperial College
and University College London in the UK. From his academic tenure,
he also brings his valuable expertise in human T lymphocyte and
their role in pathology.
Dr. Londei received his M.D. from the Faculty of Medicine at
University of Bologna and has conducted post-doctoral studies at
Tumor Immunology Unit, London, UK. He was a key member of the team
which pioneered the development of anti-TNF therapies while at the
Kennedy Institute of Rheumatology (KIR) Faculty of Medicine
Imperial College, London with professors Ravinder Maini and Marc
Feldmann. He is a widely recognized world-class contributor in the
field of inflammation and self-recognition by T lymphocytes.
Jeff Tyner, Ph.D.Dr. Tyner is a co-director of
the Translational Oncology Program for the Knight Cancer Institute,
director of the Cancer Biology Graduate Program, and a professor in
the Department of Cell, Developmental & Cancer Biology. Dr.
Tyner’s research is focused towards identification of
cancer-causing gene targets in cancer patients and identification
of patient-tailored, gene-targeted therapies. To accomplish these
objectives, he has spent the past decade developing and
implementing a functional screening approach whereby primary cells
from hematologic malignancy patients can be tested ex vivo for
sensitivity to a library of small-molecule inhibitors. This assay
has now been cumulatively applied to over 2,500 patient specimens,
and this large data set has been leveraged to inform findings that
offer new diagnostic and therapeutic options.
Dr. Tyner attended undergraduate school at Grinnell College in
Grinnell, Iowa, and graduate school at Washington University in St.
Louis. His graduate work, focusing on asthma and respiratory viral
infections, was conducted under the mentorship of Dr. Michael
Holtzman. For his post-doctoral fellowship, he joined Dr. Brian
Druker’s laboratory at OHSU where he studied molecular mechanisms
of leukemogenesis.
About RecludixRecludix is a leader in
developing platform approaches to discover potent and selective
inhibitors of challenging protein targets. The company was founded
by members of Blueprint Medicines’ founding scientific team and its
management team includes industry veterans with a track record of
success in the discovery, development and commercialization of
multiple oncology drugs. Recludix has developed a unique drug
discovery platform that integrates custom generated DNA-encoded
libraries, massively parallel determination of structure activity
relationships, and a proprietary screening tool to ensure
selectivity. The company is employing this approach first in the
development of SH2 domain inhibitors. Recludix’s most advanced
programs are focused on Signal Transducer and Activator of
Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal
activation is found in numerous cancer types, such as multiple
leukemias and lymphomas, as well as inflammatory diseases, such as
rheumatoid arthritis, asthma, atopic dermatitis inflammatory bowel
disease, and others. The company is advancing another program with
an undisclosed non-STAT SH2 domain target that also plays a
significant role in both cancer and autoimmune diseases. For more
information, please visit the company’s website at
https://recludixpharma.com.
Recludix Contacts:Alexandra Santos
asantos@wheelhouselsa.com
Aljanae Reynoldsareynolds@wheelhouselsa.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2024 to May 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From May 2023 to May 2024